Regenerative Medicine for Men’s Sexual Health: What the Evidence Shows

Regenerative approaches for male sexual dysfunction have generated substantial interest among clinicians and patients alike. This educational review examines the current evidence base for PRP, low-intensity shockwave therapy (LiSWT), stem cell therapy, and related modalities, with emphasis on guideline recommendations, regulatory context, patient selection, and what physicians need to know before incorporating these techniques into clinical practice. All applications discussed are off-label; individual results vary, and no outcome can be guaranteed.

TLDR for Busy Clinicians

• LiSWT: Strongest evidence base; EAU provides a weak recommendation for mild vasculogenic ED (Level 1a evidence)
• PRP: Growing RCT base with some positive signals, though a 2026 meta-analysis found inconsistent results for monotherapy; EAU provides no recommendation (evidence insufficient)
• Stem cells: Phase 1/2 trials only; EAU provides no recommendation; significant regulatory constraints; not ready for clinical use outside research
• BoNT-A: Experimental; only 2 RCTs; investigational use only
• HA fillers: Cosmetic enhancement procedure (not ED treatment); moderate safety data; off-label
• All applications are off-label; informed consent, documentation, and hands-on training are essential
• Results vary based on individual patient factors; no specific outcome can be guaranteed

Clinical Scenario

A 54-year-old man with a 3-year history of progressive difficulty maintaining erections presents to your clinic. He has well-controlled hypertension and type 2 diabetes. He tried sildenafil 100 mg with partial response and is now asking about “that platelet injection” he saw advertised on social media. He wants to know if it can help his situation.

This scenario reflects a common clinical encounter: a patient who has tried first-line therapy with incomplete results, has seen marketing claims online, and arrives with questions. How do you counsel him? What does the evidence actually support? This article provides a framework for that conversation.

Clinical Relevance: The Unmet Need in Men’s Sexual Health

Erectile dysfunction affects an estimated 52% of men aged 40 to 70, with prevalence increasing from approximately 40% at age 40 to approximately 70% by age 70, according to the Massachusetts Male Aging Study. An estimated 322 million men worldwide are projected to be affected by 2025. The EAU guidelines classify ED as a potential precursor of cardiovascular disease, making it both a quality-of-life concern and a cardiovascular risk marker.

First-line PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) have efficacy rates of 56 to 84% depending on dose and agent. However, at least 30% of patients do not respond adequately due to severity of underlying pathology, improper medication use, tachyphylaxis, or psychosocial factors. This treatment gap, combined with limitations of second-line options (intracavernosal injections, vacuum devices) and the invasiveness of penile prosthesis surgery, has driven interest in regenerative approaches for men’s sexual health that might address underlying tissue changes rather than providing temporary symptomatic relief.

Mechanisms of Action: How Regenerative Approaches Are Being Studied

PRP (Platelet-Rich Plasma): PRP is an autologous blood product containing concentrated platelets and growth factors. The hypothesis is that intracavernosal injection delivers growth factors (PDGF, VEGF, TGF-β) that may promote angiogenesis, tissue repair, and smooth muscle regeneration. Studies suggest PRP may support new blood vessel formation and reduce fibrosis in penile tissue, though the precise mechanisms in human erectile tissue remain under investigation.

Low-Intensity Shockwave Therapy (LiSWT): LiSWT delivers acoustic energy to penile tissue. The proposed mechanism involves inducing microtrauma that triggers neovascularization and recruitment of endogenous progenitor cells. Animal models have shown increased nitric oxide synthase expression and improved endothelial function following treatment. LiSWT is being studied for its hypothesized restorative mechanism, distinct from approaches that primarily address symptoms. However, this mechanism remains under investigation.

Stem Cell Therapy: Various cell types (bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, others) have been studied for their potential to differentiate into smooth muscle or endothelial cells and secrete paracrine factors that promote tissue repair. Research remains in early phases; clinical translation is limited.

Botulinum Toxin A (BoNT-A): This is not a regenerative therapy but is sometimes discussed alongside these modalities. BoNT-A is hypothesized to inhibit norepinephrine release from sympathetic nerve terminals, potentially promoting cavernosal smooth muscle relaxation. Its mechanism is distinct from true regenerative approaches.

It is important to note that while these mechanisms are biologically plausible, demonstrating clinical benefit in controlled trials is a separate question from demonstrating a reasonable mechanism of action. Individual responses vary significantly.

Current Evidence: What the Data Show

Low-Intensity Shockwave Therapy (LiSWT)

LiSWT has the strongest evidence base among regenerative modalities for ED. The EAU guidelines summarize the evidence at Level 1a (systematic reviews of RCTs) and provide a weak recommendation: “Use low intensity shockwave treatment (LI-SWT) with/without PDE5Is in patients with mild organic ED (vasculogenic) or post-prostatectomy (rehabilitation phase).”

A 2025 updated meta-analysis of 12 RCTs including 882 men with vasculogenic ED found statistically significant improvement in IIEF-EF and Erection Hardness Score compared to sham therapy. The authors noted these findings suggest Li-ESWT could be studied further as a potential noninvasive option, but emphasized that additional high-quality RCTs with long-term follow-up are needed.

Research published in Nature’s International Journal of Impotence Research provided treatment protocol recommendations based on three double-blind sham-controlled randomized clinical trials. The findings suggest LiST may offer benefit both as monotherapy and in combination with tadalafil across different ED severity levels. The authors noted that adding daily low-dose tadalafil appeared to enhance outcomes in their trials.

Long-term durability: A 2024 long-term follow-up from a randomized sham-controlled trial showed statistically significant improvements at 1 and 2 years, but benefits appeared to decline after 2 years, raising questions about whether repeat treatments may be needed. Individual long-term outcomes cannot be predicted.

Limitations: Optimal protocol remains undefined (energy density, number of sessions, pulse frequency, device type all vary across studies). True focused shockwave devices versus radial pressure wave devices produce different results, creating terminology confusion. LiSWT is not FDA-approved specifically for ED; use is off-label.

PRP for Erectile Dysfunction

PRP evidence is growing but remains heterogeneous, with some meta-analyses reporting positive signals and others finding inconsistent results. The EAU guidelines summarize the evidence at Level 1b and state: “Intracavernous injections of PRP have led to a mild improvement of EF among patients with organic ED, but the available evidence is still insufficient to provide a recommendation regarding its use.” No formal recommendation is provided.

A 2024 meta-analysis published in PLOS ONE analyzed 12 controlled trials involving 991 patients and 11 single-arm trials with 377 patients. The authors reported that PRP groups showed improved IIEF scores and MCID rates compared to controls, concluding PRP may be a promising area for further research.

A systematic review and meta-analysis in Translational Andrology and Urology found that IIEF-EF scores improved after 1, 3, and 6 months of PRP compared to baseline (all P<0.001). The authors concluded PRP appears to be safe and may support improvements in erectile function scores, though they emphasized the need for larger, well-designed trials.

A 2025 meta-analysis of 7 RCTs including 660 patients found IIEF scores improved at 12 weeks (p=0.03) and 24 weeks (p=0.0004) compared to control. The study also found that adding PRP to LiSWT appeared to enhance IIEF scores compared to LiSWT alone, suggesting potential benefit from combination protocols. The authors stated these findings require verification in large-scale clinical trials.

A 2026 systematic review in World Journal of Men’s Health also reported that pooled estimates favored PRP over placebo, noting improvements in ED symptoms and highlighting PRP as a potential complementary approach. However, the authors emphasized that results vary between individuals and larger trials are needed.

However, not all systematic analyses agree. A 2026 meta-analysis in the Journal of Sexual Medicine (PMID: 41288551), focusing specifically on PRP monotherapy RCTs, concluded that current evidence does not support a consistent, clinically meaningful improvement in erectile function compared with placebo, citing high heterogeneity, small sample sizes, and methodological limitations. This discrepancy may reflect differences in which studies were included, how combination vs. monotherapy protocols were handled, and the statistical methods applied. The evidence base continues to evolve.

Additionally, a Northwestern urologist stated publicly in Urology Times: “I don’t think there’s anyone for whom we have good data that PRP is efficacious. But we know it’s safe. But those are 2 important but very different things.”

Combination therapy note: The Phase 2 COCKTAIL trial presented at AUA 2024, evaluating combined SWT + PRP vs sham in 57 men, found the combination was safe but did not demonstrate statistically significant improvement in IIEF-EF over placebo. Evidence for combination protocols remains preliminary; individual outcomes cannot be predicted.

Limitations: No standardized PRP preparation protocol exists (platelet concentration, leukocyte content, activation method, injection volume, number of sessions all vary). Most studies are small (n less than 100). Follow-up periods are mostly 6 months or less. PRP is not FDA-approved for ED; use is off-label. Results vary significantly between individuals.

Stem Cell Therapy for ED

Stem cell therapy remains investigational. The EAU guidelines state: “Under investigation (phase I/II trials, n=373); safe, but efficacy conflicting (only 4 small placebo-controlled trials). Large heterogeneity; data insufficient for recommendation.” No recommendation is provided.

Published reviews note approximately 25 interventional studies registered on ClinicalTrials.gov, with only about 9 completed. Most are Phase 1/Phase 2 with 5 to 22 patients per study, focused primarily on safety as the primary endpoint. The consensus is that more research is needed before stem cell therapy can be considered for clinical use outside research settings.

Important regulatory context: The FDA has taken enforcement action against clinics marketing unapproved stem cell products. The enforcement discretion period ended May 31, 2021. Warning letters, injunctions, and lawsuits have been issued. For more on regulatory requirements, see the RMA guide to FDA guidelines on PRP and stem cell therapy.

Some products marketed as “regenerative,” including certain stem cell- and exosome-related products, may be promoted online for conditions without FDA approval. Patients and clinicians should carefully evaluate claims and discuss risks and alternatives with a qualified healthcare provider.

Botulinum Toxin A (BoNT-A) for ED

BoNT-A is experimental for ED. The EAU guidelines do not address BoNT-A for this indication. Only 2 RCTs have been published. The French AFU/SFMS guidelines note BoNT-A “might improve” ED (Level of Evidence 2), but this is based on very limited data.

Limitations: Investigational only; not a regenerative therapy; penile pain at injection site reported in 0.8 to 5.6% of patients; limited centers offer this approach; far from standard of care.

Hyaluronic Acid (HA) Fillers

HA fillers are used for penile girth enhancement, which is a cosmetic procedure, not an ED treatment. The EAU guidelines do not address HA fillers for this purpose. Evidence consists of 1 RCT (64 subjects) and retrospective studies. Safety data are moderate.

Limitations: Off-label for penile application; cosmetic enhancement only; does not address erectile function; limited long-term data.

Evidence Comparison Table

These findings describe study-level trends; they do not guarantee a clinically meaningful response for any individual patient. Results vary.

Patient Selection: Who May Be a Candidate

Based on published literature, patients most likely to show benefit in clinical trials typically have:

• Mild to moderate vasculogenic ED (for LiSWT: this is the population with the most supportive data)
• Partial response to PDE5 inhibitors (suggesting some residual vascular capacity)
• Shorter duration of ED symptoms
• Realistic expectations about evidence limitations and off-label status

Factors associated with better outcomes in trials: Research indicates that younger patients, those with milder ED, and those with shorter disease duration tend to show better responses. However, individual results vary significantly and cannot be predicted based on these factors alone.

Contraindications and cautions: Active penile infection, bleeding disorders, anticoagulation therapy, unrealistic expectations, severe or end-stage ED (where penile prosthesis may be more appropriate), and patients seeking a “cure” or “permanent fix.”

Clinicians must apply judgment and local standards when selecting patients. No published patient selection algorithm has been validated prospectively. Individual patient responses vary based on underlying etiology, severity, and other factors that cannot always be identified in advance.

When to refer to urology: Patients with severe ED unresponsive to multiple therapies, suspected Peyronie’s disease requiring surgical evaluation, patients interested in penile prosthesis, or patients with complex comorbidities affecting sexual function should be referred for subspecialty evaluation.

Practical Considerations: Training, Technique, and Documentation

Physicians considering these modalities should ensure they have appropriate hands-on training covering anatomy, injection technique, preparation standardization, and complication management. Structured regenerative medicine training programs, such as those offered by Regenerative Medicine Academy, provide curricula addressing these competencies. Training supports standardization and risk management; it does not ensure clinical outcomes.

Key practice considerations:

• Use FDA-cleared PRP preparation devices for PRP procedures
• Follow manufacturer instructions for use (IFU) for all devices
• Establish institutional protocols for technique, sterility, and outcome tracking
• Document all procedures thoroughly, including informed consent, off-label status, specific preparation parameters, injection sites, and any adverse events
• Track outcomes systematically using validated instruments (IIEF-EF, SHIM, EHS, patient satisfaction)

Risks, Adverse Events, and Regulatory Context

PRP: Generally well-tolerated. Reported adverse events include pain at injection site, bruising, and transient discomfort. Serious adverse events are rare in published literature.

LiSWT: Excellent safety profile. No serious adverse events observed in meta-analyses. Mild discomfort during treatment is common.

Stem cells: Early-phase trials report no serious adverse events, but long-term safety data are limited. Regulatory concerns regarding unapproved products are significant.

BoNT-A: Penile pain at injection site reported in 0.8 to 5.6% of patients. No systemic side effects reported in limited trials.

Regulatory status: All modalities discussed are off-label for ED. PRP is an autologous blood product exempt from FDA regulation under 21 CFR 1271.3(d), but devices used to prepare PRP require FDA 510(k) clearance (which varies by system). Clinical use for ED is off-label. Informed consent must explicitly document off-label status, evidence limitations, and alternative treatments. For detailed regulatory guidance, see the RMA guide to FDA guidelines.

Counseling Patients: Evidence-Based Conversations

When patients ask about “the P-Shot” or regenerative treatments they have seen advertised, clinicians can use a framework like the following:

“I understand why you’re interested. The safety profile of PRP is encouraging based on current studies, and some analyses suggest possible benefit, particularly for mild to moderate cases. However, the evidence is mixed. Some meta-analyses show improvements in erectile function scores, while others focusing on monotherapy have found inconsistent results. No one can guarantee a specific outcome, and results depend on individual factors including the underlying cause and severity of your ED. This would be an off-label use, meaning it is not FDA-approved for this purpose. I want to make sure you understand both the potential and the limitations before we consider this option.”

This approach acknowledges patient interest, provides honest evidence context, sets realistic expectations, and fulfills informed consent requirements.

Alternatives and Standard of Care

For completeness, clinicians should discuss established treatments as alternatives or complements to regenerative approaches:

• First-line: PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) remain the standard initial therapy
• Second-line: Intracavernosal injections (alprostadil), vacuum erection devices, intraurethral alprostadil
• Third-line: Penile prosthesis implantation
• Lifestyle modification: Exercise, weight loss, cardiovascular risk factor management (recommended by EAU guidelines as baseline for all patients)

These options should be presented neutrally and discussed alongside regenerative approaches based on patient-specific factors. For additional evidence reviews on regenerative medicine topics, visit the RMA clinical education blog.

FAQ: Common Clinician Questions

Is PRP FDA-approved for erectile dysfunction? No. PRP is exempt from HCT/P regulation as an autologous blood product, but its use for ED is off-label. PRP preparation devices may be FDA-cleared via 510(k) for certain labeled uses (which vary by system), but application for ED is not an approved indication.

What does the EAU recommend for shockwave therapy in ED? A weak recommendation for mild vasculogenic ED, with or without PDE5i (Level 1a evidence). This is the only regenerative modality with a formal EAU recommendation for ED.

What does the EAU say about PRP for ED? The EAU states evidence is insufficient to provide a recommendation. They note PRP should only be used in clinical trial settings until more data are available.

Can I offer stem cell therapy for ED in my practice? Stem cell therapy remains investigational. Products involving more than minimal manipulation may require IND approval. FDA enforcement is active. Use outside clinical trial settings carries significant regulatory and medico-legal risk.

Can I combine PRP with shockwave therapy? Some studies suggest possible synergistic benefit when combining PRP with LiSWT. A 2025 meta-analysis found improved IIEF scores with the combination vs LiSWT alone. However, the Phase 2 COCKTAIL trial did not reach statistical significance, and a 2026 meta-analysis questioned PRP monotherapy efficacy. Evidence for combination protocols is preliminary, and individual outcomes cannot be predicted.

Which patients are the best candidates for LiSWT? Based on published trials and EAU guidance: men with mild vasculogenic ED who respond partially to PDE5i. However, individual responses vary and cannot be guaranteed.

What outcome measures should I track? IIEF-EF or SHIM, Erection Hardness Score, patient satisfaction, and Doppler parameters if available. Track systematically for clinical and medico-legal purposes.

What is the expected timeline for results? Studies show changes in erectile function scores may begin at 4-12 weeks post-treatment in some patients. A long-term follow-up study showed benefits at 1-2 years but decline after 2 years. Individual timelines and durability vary significantly.

Key Takeaways

• LiSWT has the strongest evidence base and is the only regenerative modality with an EAU recommendation (weak) for mild vasculogenic ED
• PRP shows mixed results across meta-analyses; some positive, one 2026 analysis found inconsistent benefit for monotherapy; EAU provides no recommendation
• Stem cell therapy remains investigational with significant regulatory constraints; it is not ready for routine clinical use
• BoNT-A and HA fillers have very limited evidence and specific use cases (experimental and cosmetic, respectively)
• All applications are off-label; informed consent must document this clearly
• Results vary based on individual patient factors; no outcome can be guaranteed
• Structured hands-on training, systematic outcome tracking, and robust documentation are essential for safe, defensible practice integration
• Regenerative approaches should complement, not replace, standard-of-care options

Translating Evidence into Practice

Moving from literature review to safe, defensible practice requires more than reading studies. Building a standardized, defensible approach to regenerative sexual health procedures demands hands-on training covering preparation protocols, anatomy, injection technique, informed consent documentation, and complication management. Structured education bridges the gap between understanding the evidence and implementing these modalities responsibly.

Training supports standardization and risk management; it does not ensure clinical outcomes.

Ready to build clinical proficiency in regenerative sexual health? Explore evidence-based sexual health training for clinicians with hands-on, mentored instruction.

Disclaimer

Educational Content & Not Medical Advice: This article is educational content intended for licensed healthcare professionals exploring or practicing regenerative medicine. It summarizes current evidence and clinical perspectives but does not constitute medical advice. Regenerative techniques discussed may be used off-label. Individual clinical judgment, patient-specific factors, informed consent, and applicable regulations must guide all clinical decisions. Clinicians are responsible for understanding FDA status, state and national regulations, and malpractice implications before implementing any technique in practice.

Platform & Jurisdiction Note: Platform policies (Google/Meta) and state medical board advertising rules may be stricter than federal baselines; comply with the strictest applicable standard.

RMA Disclosure: RMA is an education company that provides clinician training in some of the techniques discussed in this content. This article is educational and does not constitute a claim of clinical superiority, guarantee of outcomes, or a substitute for individual clinical judgment.

Last Reviewed: February 2026